Form 4: NEUROONE CEO Reports Routine Stock Disposition

NEUROONE MEDICAL TECHNOLOGIES Corp CEO David A. Rosa reported a disposition of 2,458 common shares for tax liability.

Summary

• David A. Rosa, CEO and President of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), reported a change in beneficial ownership.
• On December 31, 2025, 2,458 shares of common stock were disposed of.
• This transaction was coded 'F', indicating a payment of tax liability by withholding securities.
• The shares were disposed of at a price of $0.758 per share.
• Following this transaction, David A. Rosa directly beneficially owns 1,153,915 shares of common stock.

Sentiment

Score: 5

Explanation: A Form 4 reporting a routine tax-related disposition of shares is neutral in sentiment regarding the company's operational performance. It reflects a standard insider transaction.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

NA

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders may note the change in direct beneficial ownership by a key executive, which is a routine part of equity compensation management.

Next Steps

• NA

Key Dates

Recommendation

The Form 4 details a routine disposition of shares by the CEO for tax liability, which is a common occurrence for executives. This transaction alone does not provide sufficient information to alter an investment thesis, thus a 'hold' recommendation is appropriate, pending further operational or financial updates from the company.

Keywords

NEUROONE MEDICAL TECHNOLOGIES, NMTC, David A. Rosa, Insider Transaction, Form 4, Common Stock, CEO, President, Stock Ownership